Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 4
2006 2
2007 5
2008 2
2009 3
2010 6
2011 4
2012 6
2013 4
2014 8
2015 5
2016 6
2017 5
2018 8
2019 10
2020 13
2021 15
2022 21
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Horak P, et al. Genet Med. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29. Genet Med. 2022. PMID: 35101336 Free PMC article.
Sarcoma classification by DNA methylation profiling.
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler KW, Reinhardt A, Wefers AK, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss FKF, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik AE, Kool M, Romero-Pérez L, Grünewald TGP, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers YMH, Weidema ME, Mentzel T, Griewank K, de Álava E, Martín JD, Gastearena MAI, Chang KT, Low SYY, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner VF, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens WNM, Brandner S, Jaunmuktane Z, Lyskjær I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado OM, Sáinz-Jaspeado M, Mora J, Alonso J, Del Muro XG, Moran S, Esteller M, Benhamida JK, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hart… See abstract for full author list ➔ Koelsche C, et al. Among authors: horak p. Nat Commun. 2021 Jan 21;12(1):498. doi: 10.1038/s41467-020-20603-4. Nat Commun. 2021. PMID: 33479225 Free PMC article.
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H, Fröhling S. Horak P, et al. Cancer Discov. 2021 Nov;11(11):2780-2795. doi: 10.1158/2159-8290.CD-21-0126. Epub 2021 Jun 10. Cancer Discov. 2021. PMID: 34112699
Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Volckmar AL, Renner M, Kirchner M, Heilig CE, Neumann O, Schirmacher P, Fröhling S, Stenzinger A. Horak P, et al. Pathologe. 2021 Nov;42(6):602. doi: 10.1007/s00292-021-01002-y. Pathologe. 2021. PMID: 34605937 German. No abstract available.
Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.
Wurm AA, Brilloff S, Kolovich S, Schäfer S, Rahimian E, Kufrin V, Bill M, Carrero ZI, Drukewitz S, Krüger A, Hüther M, Uhrig S, Oster S, Westphal D, Meier F, Pfütze K, Hübschmann D, Horak P, Kreutzfeldt S, Richter D, Schröck E, Baretton G, Heining C, Möhrmann L, Fröhling S, Ball CR, Glimm H. Wurm AA, et al. Among authors: horak p. Cell Rep Med. 2023 Oct 17;4(10):101200. doi: 10.1016/j.xcrm.2023.101200. Epub 2023 Sep 20. Cell Rep Med. 2023. PMID: 37734378 Free PMC article.
Measuring Progress in Precision Oncology.
Horak P, Fröhling S. Horak P, et al. Cancer Discov. 2024 Jan 12;14(1):18-19. doi: 10.1158/2159-8290.CD-23-1237. Cancer Discov. 2024. PMID: 38213297
TUSC3: functional duality of a cancer gene.
Vašíčková K, Horak P, Vaňhara P. Vašíčková K, et al. Among authors: horak p. Cell Mol Life Sci. 2018 Mar;75(5):849-857. doi: 10.1007/s00018-017-2660-4. Epub 2017 Sep 19. Cell Mol Life Sci. 2018. PMID: 28929175 Review.
Response to Mehta et al.
Horak P, Chakravarty D, Sonkin D. Horak P, et al. Genet Med. 2022 Sep;24(9):1989-1990. doi: 10.1016/j.gim.2022.05.018. Epub 2022 Jul 7. Genet Med. 2022. PMID: 35796744 Free article. No abstract available.
[Precision oncology and molecular tumor boards].
Mack E, Horak P, Fröhling S, Neubauer A. Mack E, et al. Among authors: horak p. Inn Med (Heidelb). 2024 May;65(5):462-471. doi: 10.1007/s00108-024-01689-0. Epub 2024 Apr 23. Inn Med (Heidelb). 2024. PMID: 38652307 Review. German.
Tumour mutational burden and survival with molecularly matched therapy.
de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I. de Bortoli T, et al. Among authors: horak p. Eur J Cancer. 2023 Sep;190:112925. doi: 10.1016/j.ejca.2023.05.013. Eur J Cancer. 2023. PMID: 37544709
130 results